Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · IEX Real-Time Price · USD
9.69
+0.12 (1.25%)
Jul 22, 2024, 10:06 AM EDT - Market open
Theravance Biopharma Employees
Theravance Biopharma had 99 employees as of December 31, 2023. The number of employees decreased by 12 or -10.81% compared to the previous year.
Employees
99
Change (1Y)
-12
Growth (1Y)
-10.81%
Revenue / Employee
$621,313
Profits / Employee
-$452,212
Market Cap
466.88M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Enhabit | 10,800 |
Bioventus | 970 |
biote | 194 |
Fate Therapeutics | 181 |
Voyager Therapeutics | 162 |
MaxCyte | 143 |
EyePoint Pharmaceuticals | 121 |
Third Harmonic Bio | 30 |
TBPH News
- 4 hours ago - Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024 - PRNewsWire
- 2 months ago - Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update - PRNewsWire
- 2 months ago - Theravance Biopharma to Participate in an Upcoming Investor Conference - PRNewsWire
- 3 months ago - Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024 - PRNewsWire
- 3 months ago - Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024 - PRNewsWire
- 5 months ago - Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - PRNewsWire
- 5 months ago - Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024 - PRNewsWire
- 7 months ago - Theravance Biopharma's stock slides 21% after Phase 4 trial of COPD treatment fails to meet main goal - Market Watch